Defyrus Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Defyrus General Information

Description

Developer of drugs for infectious viral diseases designed to countermeasure bioterrorist threats and emerging diseases. The company's drugs fight infectious viral diseases worldwide for public health and biodefence missions, enabling patients to get products that naturally stimulate the human immune response.

Contact Information

Website
www.defyrus.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2 Bloor Street West
  • Suite 2602
  • Toronto, Ontario M4W 3E2
  • Canada
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2 Bloor Street West
  • Suite 2602
  • Toronto, Ontario M4W 3E2
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Defyrus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jul-2020 Completed Out of Business
3. Later Stage VC 01-Jan-2019 Completed Generating Revenue
2. Secondary Transaction - Private 01-Jan-2018 $3.72M Completed Startup
1. Early Stage VC (Series A) 23-Oct-2008 $3.72M $3.72M Completed Startup
To view Defyrus’s complete valuation and funding history, request access »

Defyrus Patents

Defyrus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2764759-A1 Administration of interferon for prophylaxis against or treatment of pathogenic infection Inactive 09-Jun-2009
EP-2440251-A1 Administration of interferon for prophylaxis against or treatment of pathogenic infection Inactive 09-Jun-2009
EP-2440251-A4 Administration of interferon for prophylaxis against or treatment of pathogenic infection Inactive 09-Jun-2009
US-20110000480-A1 Administration of interferon for prophylaxis against or treatment of pathogenic infection Active 09-Jun-2009
US-20130315952-A1 Administration of interferon for prophylaxis against or treatment of pathogenic infection Inactive 09-Jun-2009 A61K38/212
To view Defyrus’s complete patent history, request access »

Defyrus Investments (1)

Defyrus’s most recent deal was a Joint Venture with Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical). The deal was made on 29-Jul-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) 29-Jul-2013 Joint Venture Buildings and Property
To view Defyrus’s complete investments history, request access »

Defyrus FAQs

  • When was Defyrus founded?

    Defyrus was founded in 2008.

  • Where is Defyrus headquartered?

    Defyrus is headquartered in Toronto, Canada.

  • What industry is Defyrus in?

    Defyrus’s primary industry is Drug Discovery.

  • Is Defyrus a private or public company?

    Defyrus is a Private company.

  • What is Defyrus’s current revenue?

    The current revenue for Defyrus is .

  • How much funding has Defyrus raised over time?

    Defyrus has raised $3.72M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process